CRISPR Therapeutics vs Dyadic International
CRISPR Therapeutics reported revenue of $4 million in fiscal 2025, about the same as Dyadic International's $3 million in fiscal 2025. CRISPR Therapeutics' revenue fell 90.6% in its latest year, and Dyadic International's fell 11.6%. CRISPR Therapeutics had an operating margin of -18933.7%, against -232.8% at Dyadic International.
Side by side
| CRISPR Therapeutics | Dyadic International | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4M | $3M |
| Revenue growth | −90.6% | −11.6% |
| Revenue growth a year, last 5 years | 38.0% | 14.1% |
| Gross margin | — | 24.9% |
| Operating margin | −18,933.7% | −232.8% |
| Net margin | −16,569.8% | −238.3% |
| Free cash flow | −$346M | — |
| Free cash flow margin | −9,855.5% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.6% | 11.3% |
| Last close | $38.93 | $0.31 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $14.5 million | sold $124,914 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CRISPR TherapeuticsDyadic International
Operating margin
Percent of revenue
CRISPR TherapeuticsDyadic International
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CRISPR TherapeuticsDyadic International
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CRISPR Therapeutics and Dyadic International pages.